Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2018

01-02-2018 | Epidemiology

Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ

Published in: Breast Cancer Research and Treatment | Issue 3/2018

Login to get access

Abstract

Background

Ductal carcinoma in situ (DCIS) is a neoplastic proliferation of epithelial cells which is confined within the basement membrane of the mammary ductal–lobular system. It is of interest to determine to what extent the potential to metastasize increases for DCIS patients when the basement membrane is breached (i.e. microinvasion is present).

Methods

We retrieved the records of 525,395 women who had either first primary DCIS or small (≤ 2.0 cm) node-negative invasive breast cancer in the Surveillance, Epidemiology and End Results (SEER) registries database (1990–2013). For each patient, we extracted information on year of diagnosis, age at diagnosis, tumour size, tumour grade, oestrogen receptor status, use of radiotherapy, type of surgery, cause of death and follow-up time. We classified patients into four groups, according to the size of the invasive component of the primary tumour. We estimated the actuarial rate of breast cancer-specific mortality at ten and 20 years for women in each size category.

Results

We identified 161,394 women with pure DCIS, 13,489 women with microinvasive carcinoma (≤ 0.1 cm of invasion), 153,856 women with invasive cancer 0.2–1.0 cm in size and 196,656 women with invasive cancer 1.1–2.0 cm in size. The 20-year actuarial breast cancer-specific mortality rate was 3.8% for women with pure DCIS, was 6.9% for women with microinvasive carcinoma, was 6.8% for women with invasive cancer 0.2–1.0 cm in size and was 12.1% for women with invasive cancer 1.1–2.0 cm in size. The adjusted hazard ratio for death associated with microinvasive carcinoma (vs. pure DCIS) was 2.00 (95% CI 1.76–2.26; p < 0.0001).

Conclusions

In terms of prognosis, microinvasive cancer more closely resembles small invasive cancer 0.2–1.0 cm) than pure DCIS. For invasive cancers under 1.0 cm, size has little impact on mortality.
Literature
1.
go back to reference Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast. IARC, Lyon Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) (2012) WHO classification of tumours of the breast. IARC, Lyon
2.
go back to reference Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
3.
go back to reference Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS (2000) Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg 180:305–308CrossRefPubMed Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS (2000) Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg 180:305–308CrossRefPubMed
4.
5.
6.
go back to reference Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44:2684–2689CrossRefPubMed Shatat L, Gloyeske N, Madan R, O’Neil M, Tawfik O, Fan F (2013) Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics. Hum Pathol 44:2684–2689CrossRefPubMed
7.
go back to reference Silver SA, Tavassoli FA (1998) Mammary ductal carcinoma in situ with microinvasion. Cancer 82:2382–2390CrossRefPubMed Silver SA, Tavassoli FA (1998) Mammary ductal carcinoma in situ with microinvasion. Cancer 82:2382–2390CrossRefPubMed
8.
go back to reference Schnitt SJ, Collins LC (eds) (2013) Microinvasive carcinoma: biopsy interpretation of the breast. Wolters Kluwer Lippincott Williams and Wilkins, Philadelphia, pp 267–280 Schnitt SJ, Collins LC (eds) (2013) Microinvasive carcinoma: biopsy interpretation of the breast. Wolters Kluwer Lippincott Williams and Wilkins, Philadelphia, pp 267–280
9.
go back to reference Prasad ML, Osborne MP, Giri DD, Hoda SA (2000) Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 24:422–428CrossRefPubMed Prasad ML, Osborne MP, Giri DD, Hoda SA (2000) Microinvasive carcinoma (T1mic) of the breast: clinicopathologic profile of 21 cases. Am J Surg Pathol 24:422–428CrossRefPubMed
10.
go back to reference Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS (2000) Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 88:1403–1409CrossRefPubMed Padmore RF, Fowble B, Hoffman J, Rosser C, Hanlon A, Patchefsky AS (2000) Microinvasive breast carcinoma: clinicopathologic analysis of a single institution experience. Cancer 88:1403–1409CrossRefPubMed
11.
go back to reference Margalit DN, Sreedhara M, Chen YH et al (2013) Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 20:811–818CrossRefPubMed Margalit DN, Sreedhara M, Chen YH et al (2013) Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy. Ann Surg Oncol 20:811–818CrossRefPubMed
12.
go back to reference Solin LJ, Fowble B, Yeh IT et al (1992) Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 23:961–968CrossRefPubMed Solin LJ, Fowble B, Yeh IT et al (1992) Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys 23:961–968CrossRefPubMed
13.
go back to reference Silverstein MJ, Waisman JR, Gamagami P et al (1990) Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 66:102–108CrossRefPubMed Silverstein MJ, Waisman JR, Gamagami P et al (1990) Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 66:102–108CrossRefPubMed
14.
go back to reference Sue GR, Lannin DR, Killelea B, Chagpar AB (2013) Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 206:478–481CrossRefPubMed Sue GR, Lannin DR, Killelea B, Chagpar AB (2013) Predictors of microinvasion and its prognostic role in ductal carcinoma in situ. Am J Surg 206:478–481CrossRefPubMed
15.
go back to reference Ozkan-Gurdal S, Cabioglu N, Ozcinar B et al (2014) Factors predicting microinvasion in ductal carcinoma in situ. Asian Pac J Cancer Prev 15:55–60CrossRefPubMed Ozkan-Gurdal S, Cabioglu N, Ozcinar B et al (2014) Factors predicting microinvasion in ductal carcinoma in situ. Asian Pac J Cancer Prev 15:55–60CrossRefPubMed
16.
go back to reference Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM (2011) Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol 18:1342–1348CrossRefPubMed Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, Shao ZM (2011) Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol 18:1342–1348CrossRefPubMed
17.
go back to reference Mori M, Tsugawa K, Yamauchi H et al (2013) Pathological assessment of microinvasive carcinoma of the breast. Breast Cancer 20:331–335CrossRefPubMed Mori M, Tsugawa K, Yamauchi H et al (2013) Pathological assessment of microinvasive carcinoma of the breast. Breast Cancer 20:331–335CrossRefPubMed
18.
go back to reference Gradishar WJ, Anderson BO, Balassanian R et al (2015) Breast Cancer Version 2.2015. J Natl Compr Cancer Netw 13:448–475CrossRef Gradishar WJ, Anderson BO, Balassanian R et al (2015) Breast Cancer Version 2.2015. J Natl Compr Cancer Netw 13:448–475CrossRef
19.
go back to reference Matsen CB, Hirsch A, Eaton A et al (2014) Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases. Ann Surg Oncol 21:3330–3335CrossRefPubMedPubMedCentral Matsen CB, Hirsch A, Eaton A et al (2014) Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases. Ann Surg Oncol 21:3330–3335CrossRefPubMedPubMedCentral
20.
go back to reference Wang L, Zhang W, Lyu S et al (2015) Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol 36:2241–2248CrossRefPubMed Wang L, Zhang W, Lyu S et al (2015) Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast. Tumour Biol 36:2241–2248CrossRefPubMed
21.
go back to reference Parikh RR, Haffty BG, Lannin D, Moran MS (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82:7–13CrossRefPubMed Parikh RR, Haffty BG, Lannin D, Moran MS (2012) Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation. Int J Radiat Oncol Biol Phys 82:7–13CrossRefPubMed
22.
go back to reference de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM (2002) Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 94:2134–2142CrossRefPubMed de Mascarel I, MacGrogan G, Mathoulin-Pélissier S, Soubeyran I, Picot V, Coindre JM (2002) Breast ductal carcinoma in situ with microinvasion: a definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 94:2134–2142CrossRefPubMed
24.
go back to reference Niu HF, Wei LJ, Yu JP et al (2016) Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery? Cancer Biol Med 13:142–149CrossRefPubMedPubMedCentral Niu HF, Wei LJ, Yu JP et al (2016) Is adjuvant chemotherapy necessary for patients with microinvasive breast cancer after surgery? Cancer Biol Med 13:142–149CrossRefPubMedPubMedCentral
25.
go back to reference Kwon JH, Kim YJ, Lee KW et al (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557CrossRefPubMedPubMedCentral Kwon JH, Kim YJ, Lee KW et al (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557CrossRefPubMedPubMedCentral
26.
go back to reference Wang W, Zhu W, Du F, Luo Y, Xu B (2017) The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: A SEER database analysis. Sci Rep 7:42045CrossRefPubMedPubMedCentral Wang W, Zhu W, Du F, Luo Y, Xu B (2017) The demographic features, clinicopathological characteristics and cancer-specific outcomes for patients with microinvasive breast cancer: A SEER database analysis. Sci Rep 7:42045CrossRefPubMedPubMedCentral
27.
go back to reference Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ (2009) Diagnosis and management of ductal carcinoma in situ (DCIS). Evidence Report/Technology Assessment No. 185. AHRQ Publication No. 09-E018. Agency for Healthcare Research and Quality, Rockville Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt TJ (2009) Diagnosis and management of ductal carcinoma in situ (DCIS). Evidence Report/Technology Assessment No. 185. AHRQ Publication No. 09-E018. Agency for Healthcare Research and Quality, Rockville
28.
go back to reference El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K (2017) Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg 213:171–180CrossRef El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K (2017) Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg 213:171–180CrossRef
29.
go back to reference Zetterlund L, Stemme S, Arnrup H, de Boniface J (2014) Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg 101:488–494CrossRefPubMed Zetterlund L, Stemme S, Arnrup H, de Boniface J (2014) Incidence of and risk factors for sentinel lymph node metastasis in patients with a postoperative diagnosis of ductal carcinoma in situ. Br J Surg 101:488–494CrossRefPubMed
30.
go back to reference Osako T, Iwase T, Kimura K, Horii R, Akiyama F (2013) Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis. Cancer Sci 104:453–457CrossRefPubMed Osako T, Iwase T, Kimura K, Horii R, Akiyama F (2013) Detection of occult invasion in ductal carcinoma in situ of the breast with sentinel node metastasis. Cancer Sci 104:453–457CrossRefPubMed
31.
go back to reference Lakhani SR (1999) The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187:272–278CrossRefPubMed Lakhani SR (1999) The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 187:272–278CrossRefPubMed
32.
go back to reference Yang M, Moriya T, Oguma M et al (2003) Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53:422–428CrossRefPubMed Yang M, Moriya T, Oguma M et al (2003) Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53:422–428CrossRefPubMed
33.
go back to reference Tulusan AH, Grünsteidel W, Ramming I, Egger H (1982) A contribution to the natural history of breast cancer. III. Changes in the basement membranes in breast cancers with stromal microinvasion. Arch Gynecol 231:209–218CrossRefPubMed Tulusan AH, Grünsteidel W, Ramming I, Egger H (1982) A contribution to the natural history of breast cancer. III. Changes in the basement membranes in breast cancers with stromal microinvasion. Arch Gynecol 231:209–218CrossRefPubMed
34.
go back to reference Elling D, Vesper AS, Fiedler B, Martin H, Krocker J (2001) Intraductal component in invasive breast cancer: analysis of 250 resected surgical specimens. Breast 10:405–410CrossRefPubMed Elling D, Vesper AS, Fiedler B, Martin H, Krocker J (2001) Intraductal component in invasive breast cancer: analysis of 250 resected surgical specimens. Breast 10:405–410CrossRefPubMed
35.
go back to reference Cedolini C, Bertozzi S, Londero AP et al (2015) Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Int J Clin Exp Pathol 8:13304–13313PubMedPubMedCentral Cedolini C, Bertozzi S, Londero AP et al (2015) Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer. Int J Clin Exp Pathol 8:13304–13313PubMedPubMedCentral
36.
go back to reference Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102:1391–1396CrossRefPubMedPubMedCentral Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102:1391–1396CrossRefPubMedPubMedCentral
38.
go back to reference Tubiana M, Koscielny S (1999) The rationale for early diagnosis of cancer–the example of breast cancer. Acta Oncol 38:295–303CrossRefPubMed Tubiana M, Koscielny S (1999) The rationale for early diagnosis of cancer–the example of breast cancer. Acta Oncol 38:295–303CrossRefPubMed
40.
go back to reference Karnofsky Hellman S, Lecture Memorial (1994) Natural history of small breast cancers. J Clin Oncol 12:2229–2234CrossRef Karnofsky Hellman S, Lecture Memorial (1994) Natural history of small breast cancers. J Clin Oncol 12:2229–2234CrossRef
41.
go back to reference Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960CrossRefPubMed Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960CrossRefPubMed
42.
go back to reference Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MM (2015) Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173,797 patients. BMJ 351:h4901CrossRefPubMedPubMedCentral
43.
go back to reference Wo JY, Chen K, Neville BA, Lin NU, Punglia RS (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29:2619–2627CrossRefPubMedPubMedCentral Wo JY, Chen K, Neville BA, Lin NU, Punglia RS (2011) Effect of very small tumor size on cancer-specific mortality in node-positive breast cancer. J Clin Oncol 29:2619–2627CrossRefPubMedPubMedCentral
44.
go back to reference Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer–a reappraisal. Nat Rev Clin Oncol 7:348–353CrossRefPubMed Foulkes WD, Reis-Filho JS, Narod SA (2010) Tumor size and survival in breast cancer–a reappraisal. Nat Rev Clin Oncol 7:348–353CrossRefPubMed
45.
go back to reference Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM (2012) Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc 87:1171–1180CrossRefPubMedPubMedCentral Yu KD, Jiang YZ, Chen S, Cao ZG, Wu J, Shen ZZ, Shao ZM (2012) Effect of large tumor size on cancer-specific mortality in node-negative breast cancer. Mayo Clin Proc 87:1171–1180CrossRefPubMedPubMedCentral
46.
go back to reference Zheng YZ, Wang L, Hu X, Shao ZM (2015) Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget 6:22985–22995PubMedPubMedCentral Zheng YZ, Wang L, Hu X, Shao ZM (2015) Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. Oncotarget 6:22985–22995PubMedPubMedCentral
Metadata
Title
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ
Publication date
01-02-2018
Published in
Breast Cancer Research and Treatment / Issue 3/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4572-2

Other articles of this Issue 3/2018

Breast Cancer Research and Treatment 3/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine